Company* (Symbol) | Product | Description | Indication | Status (Date) |
CANCER |
||||
Aastrom Biosciences Inc.* | CB-II Therapy Kit | Produces umbilical cord blood stem cells | Leukemia | Company initiated a Phase I/II study of the kit for the production of umbilical cord blood stem cells; study will evaluate the rate of normal blood cell recovery and the survival rate of leukemia patients following AastromReplicell System-produced cord blood stem cell transplant (11/16) |
Allos Therapeutics Inc. (ALTH) | RSR13 | Synthetic allosteric modifier of hemoglobin that noncovalently binds to hemoglobin, increasing oxygen delivery to hypoxic tissue | Non-small-cell lung cancer | Company said 87% of patients treated with induction chemotherapy in conjunction with radiation and RSR13 showed a complete or partial response (11/29) |
Antigenics Inc. (AGEN) | Oncophage | Uses heat shock proteins to activate cellular immune responses | Pancreatic cancer | Company expanded its Phase I/II trial to include feasibility and survival as the objectives (11/27) |
Atrix Laboratories Inc. (ATRX) | Leuprogel | Leuprolide acetate delivered using Atrix's Atrigel delivery system; administered as a 3-month sustained-release dose subcutaneously | Prostate cancer | Company completed enrollment in its 110-patient Phase III trial (11/21) |
AVAX Technologies Inc. (AVXT) | M-Vax | Haptenized autologous cell vaccine | Melanoma | New data presented at the 18th Chemotherapy Foundation Symposium showed the 2-year survival of patients treated with M-Vax was 60%; company said the safety profile is excellent (11/13) |
AVI BioPharma Inc. (AVII) | Avicine | Drug elicits a highly specific immune response to hCG; non-toxic immunotherapy | Pancreatic cancer | AVI completed patient enrollment in its Phase II trial involving 50 patients (11/14) |
Biomira Inc. (BIOM; TSE:BRA) | Theratope | Synthetic carbohydrate-based vaccine; mimic of cancer antigen si alyl-Tn plus carrier molecule KLH | Metastatic breast cancer | Company said it enrolled 819 of 900 evaluable patients in its Phase III trial (11/30) |
Celgene Corp. (CELG) | Thalomid (FDA-approved) | Thalidomide; thought to act by modulating levels of tumor necrosis factor-alpha | Multiple myeloma | Updated clinical trial data showed Thalomid produced a 55% overall survival rate and a 30% event-free survival 18 months after therapy began (11/10) |
Dendreon Corp. (DNDN) | Provenge | Vaccine; antigen-loaded dendritic cell therapy | Prostate cancer | Study results show the vaccine is safe and well tolerated (11/30) |
EntreMed Inc. (ENMD) | Endostatin | Recombinant human Endostatin protein | Tumors | Data from Phase I trials showed no safety concerns (11/9) |
Enzon Inc. (ENZN) | Prothecan | PEG-enhanced version of campothecin, believed to be a topoisomerase inhibitor | Cancer | Phase I results presented at the 11th NCI/EORTC/AACR Symposium showed the drug was well tolerated and demonstrated antitumor activity (11/7) |
Genta Inc. (GNTA) | Genasense | Antisense compound; synthetic DNA strands that bind to mRNA for the bc12 gene (proto-oncogene) | Cancer | Phase I/II results published in the Nov. 18 issue of The Lancet showed Genasense reduced levels of Bcl-2 protein, caused major antitumor responses and possibly extended the life of patients, when used in combination with dacarbazine (11/17) |
Gilead Sciences Inc. (GILD) | NX 211 | Liposomal formulation of a novel topoisomerase 1 inhibitor | Relapsed ovarian cancer | Gilead initiated the first Phase II clinical trial of NX 211 in patients resistant to treatment with top-otecan (11/2) |
Hybridon Inc. (OTC BB:HYBN) | GEM 231 | Mixed-backbone oligo-nucleotide that targets the RIa regulatory subunit of protein kinase A | Cancer | Phase I data showed the drug's side effects were mild and reversible; data were presented at the 11th annual NCI/EORTC/AACR Symposium (11/10) |
ImClone Systems Inc. (IMCL) | IMC C225 | Designed to target and block the epidermal growth factor receptor | Irinotecan-refractory colorectal carcinoma | Preliminary results from a Phase II study demonstrated anticancer activity of the combined use of IMC C225 and irinotecan resulting in tumor shrinkage and a slowing of disease progression (11/8) |
ImmunoGen Inc. (IMGN) and Smith-Kline Beecham (NYSE:SBH) | huC242-DM1/SB-408075 | Tumor-Activated Prodrug | Colorectal, pancreatic and non-small-cell lung cancer | Company announced favorable safety data in a Phase I/II trial (11/10) |
Introgen Therapeutics Inc. (INGN) | INGN 241 | Adenoviral-mda7, apoptosis-inducing compound | Cancer | Company initiated a Phase I trial (11/30) |
Isis Pharmaceuticals Inc. (ISIP) | ISIS 3521 | Antisense protein kinase C-alpha inhibitor that binds to an mRNA sequence specific to PKC-alpha | Non-small-cell lung cancer | Phase I/II data presented at the 11th Annual NCI/EORTC/AACR Symposium on New Drugs in Cancer Therapy showed the drug in combination with standard chemotherapy agents has promising activity, based on survival time and response rate (11/10) |
Large Scale Biology Corp. (LSBC) | ND | Vaccine | B-cell non-Hodgkin's lymphoma | Company initiated a Phase I trial designed to evaluate the vaccine's safety and preliminary immune response-generation ability (11/16) |
Ligand Pharmaceuticals Inc. (LGND) | Targretin (FDA-approved) | Bexarotene capsules; synthetic retinoid analogue that selectively activates retinoid X receptors | Non-small-cell lung cancer | Company announced at the NCI/EORTC/AACR meeting that Phase I/II trial results demonstrated that Targretin in conjunction with chemotherapy yielded acceptable response rates, with beter-than-expected survival (11/8) |
Magainin Pharmaceuticals Inc. (MAGN) | Squalamine | Combination therapy with standard chemotherapy of carboplatin and paclitaxel | Non-small-cell lung cancer | Company said it observed a 50% or greater reduction in tumor size in 36% of 22 Stage IIIB or Stage IV non-small-cell lung cancer patients; overall, 31% experienced objective responses at various doses (11/16) |
Maret Pharmaceuticals Inc.* | MARstem | Hematopoietic therapy; peptide analogue of the human hormone angiotensin | Pancytopenia in breast cancer patients | Phase I/II trial results showed the compound reduced the frequency of certain grades of thrombocytopenia, anemia and lymphopenia; the compound exhibited an excellent safety profile (11/10) |
Matrix Pharmaceuticals Inc. (MATX) | IntraDose Injectable Gel | Biodegradable gel containing cisplatin and epinephrine | Unresectable liver tumors | Phase II data showed 55% of treated patients demonstrated at least a 50% reduction in tumor size (11/29) |
MGI Pharma Inc. (MOGN) | Irofulven | Hydroxymethylacylfulvene | Advanced pancreatic | Phase II data presented at the 11th NCI/EORTC/AACR Symposium on New Drugs in Cancer Therapy showed that 10 of 53 patients achieved six-month survival, the primary endpoint of the trial (11/9) |
MGI Pharma Inc. (MOGN) and MethylGene Inc. (Canada)* | MG98 | Second-generation mRNA inhibitor that inhibits methyltransferase | Recurrent or metastatic squamous cell cancer of the neck and head | Companies initiated a Phase II trial (11/16) |
Millennium Pharmaceuticals Inc. (MLNM) | LDP-341 | Proteasome inhibitor | Cancer | Preclinical and clinical studies showed the drug induces apoptosis, reduces tumor volume and shows activity in combination with standard chemotherapy agents or radiation (11/10) |
Onyx Pharmaceuticals Inc. (ONXX) | CI-1042 | Therapeutic virus that selectively replicates in and kills cancer cells with abnormal p53 function | Cancer | Two clinical studies presented at the NCI/EORTC/AACR Symposium on New Drugs in Cancer Therapy showed the compound in combination with total body radiation produces higher antitumor activity than each treatment strategy alone (11/13); Phase II results showed the drug replicates in tumors and causes regression in refractory head and neck cancers (11/20) |
OSI Pharmaceuticals Inc. (OSIP) | OSI-774 | Orally active inhibitor of the epidermal growth factor receptor | Advanced, refractory non-small-cell lung | Company said the drug produced either a partial response or evidence of disease stabilization after three months of daily oral dosing in 48% of 56 patients in a Phase II study (11/9) |
Oxford BioMedica plc (UK)* | MetXia | Delivers the human gene CYP2B6 to tumors, where it produces an enzyme that converts a previously circulating prodrug into the active form of the cytotoxic cylclophosphamide | Cancer | Phase I/II data showed the product was safe and well tolerated and resulted in gene transfer to the tumors (11/15**) |
Peregrine Pharmaceuticals Inc. (PPHM) | Cotara | Tumor necrosis therapy; chimeric monoclonal antibody that targets DNA-associated histone antigens, labeled with I-131 | Colorectal cancer | Company enrolled and treated the first patient in its Phase I study (11/30) |
Progen Industries Ltd. (Australia; PGLAF) | PI-88 | Sulfated oligosaccharide anti-angiogenic agent | Cancer | Company completed recruitment for a Phase Ib trial and is planning Phase II trials (11/27) |
Ribozyme Pharmaceuticals Inc. (RZYM) | Angiozyme | Antiangiogenic ribozyme targeting vascular endothelial growth factor | Cancer | Results of a Phase I/II trial reported at the annual European Organization for Treatment of Cancer Conference showed Angiozyme was well tolerated and demonstrated good bioavailability (11/9) |
SciClone Pharmaceuticals Inc. (SCLN) | Zadaxin | Synthetic immunostimulant peptide | Malignant melanoma | Company initiated a clinical study designed to evaluate Zadaxin's ability to enhance immunity, elevate T-cell counts and contribute to specific melanoma immune response (11/20) |
SuperGen Inc. (SUPG) | Decitabine | Inhibits DNA methyltransferase activity | Sickle cell anemia; myelodysplastic syndrome; chronic myelogenous leukemia | Company said its anticancer compound generated a 100% response in anemia patients test in a Phase I/II study; the data were published in the October issue of Blood (11/2); company said three studies show the drug produced a response rate in 49% of 125 myelodysplastic syndrome patients tested and a 62% response rate among 81 chronic myelogenous leukemia patients (11/8) |
SuperGen Inc. (SUPG) | Nipent | Pentostatin | Refractory blood cancers | Data from two studies indicate Nipent in combination therapy with Rituximab produces response rates of nearly 100%; a study of pentostatin and cyclophosphamide in patients with chronic lymphocytic leukemia produced a response rate of 71% in 14 evaluable patients and 22% in the 21 patients enrolled (11/13) |
Telik Inc. (TELK) | TLK286 | Small-molecule drug, developed with Telik's TRAP chemogenetics technology, that targets tumors that overexpress GST P1-1 | Advanced solid tumors or non-Hodgkin's lymphoma that has resisted standard therapy | Positive interim Phase I results< were presented at the 11th annual NCI/EORTC/AACR Symposium on New Drugs in Cancer Therapy showing the drug was well tolerated (11/8) /TD> |
XOMA Ltd. (XOMA) | ING-1 Human Engineered monoclonal antibody< | Designed to bring about tumor death by recognizing and binding to the EpCAM antigen | Cancer | Xoma initiated a Phase I study of its antibody in cancer patients (11/1) |
CARDIOVASCULAR |
||||
Andrx Corp. (ADRX) | Lovastin XL | HMG-CoA reductase inhibitor | Dyslipidemia | Company completed the pivotal Phase III trials of Lovastin XL to treat patients with dyslipidemia at risk for cardiovascular disease; company expects to file an NDA in the first quarter of 2001 (11/13) |
Avant Immunotherapeutics Inc. (AVAN) | TP10 | Soluble form of complement receptor 1, designed to inhibit complement proteins | Cardiopulmonary bypass surgery | Avant began a 600-patient, placepo-controlled Phase II trial of TP10designed to assess its ability to mitigate injury to the heart, brain and other organs while patients are placed on cardiopulmonary bypass circuits (11/27) |
AVI BioPharma (AVII) | Neugene | Antisense drug | Cardiovascular restenosis | Company announced the completion of a Phase I trial showing the drug did not display any safety issues; Neugene now is in a Phase II study; the company expects to begin additional trials in cancer and polycystic kidney disease (11/9) |
COR Therapeutics (CORR) and Schering-Plough (NYSE:SGP) | Integrilin | Anti-platelet agent; GP IIb-IIIa inhibitor | Myocardial infarction | Phase II results presented at the 2000 Scientific Sessions of the American Heart Association show Integrilin combined with half-dose alteplase significantly improved blood flow through clogged arteries, compared with full-dose alteplase alone; preliminary results from another Phase II study of Integrilin with reduced-dose TNKase showed patients achieved restoration of blood flow at 60 minutes and displayed similar adverse reactions as with full-dose TNKase alone (11/14) |
Corvas International Inc. (CVAS) | UK-279,276 | recombinant neutrophil inhibitory factor | Acute stroke | Pfizer initiated a Phase IIb dose-ranging study to determine the efficacy and safety of the agent (11/28) |
CV Therapeutics Inc. (CVTX) | CVT-510 | Selective A1 adenosine receptor agonist | Paroxysmal supraventricular tachycardia (PVST) (atrial arrhythmia) | Phase II results presented at the 73rd Scientific Sessions of the American Heart Association indicate CVT-510 terminated PVST without adversely affecting blood pressure (11/14) |
CV Therapeutics Inc. (CVTX) and Fujisawa Healthcare Inc. (unit of Fujisawa Pharmaceutical Co. Ltd.; Japan) | CVT-3146 | A selective A2A adenosine receptor agonist | Cardiac perfusion | Companies initiated a Phase I trial (11/29) |
Discovery Laboratories Inc. (DSCO) | Surfaxin | Peptide sinapultide | Acute respiratory distress syndrome | Company received clearance to begin a Phase II trial in 110 patients (11/16) |
Esperion Therapeutics Inc. (ESPR) | ApoA-I Milano | A variant of ApoA-1 that is believed to protect against vascular disease by extracting cholesterol from the artery wall and transporting it to the liver for removal | Cardiovascular and metabolic diseases | Company initiated a Phase I trial (11/9) |
Esperion Therapeutics Inc. (ESPR) | LUVs | Unilamellar vesicles; spherical particles comprised of naturally occuring lipids that recirculate through arteries | Vascular disease | Company completed its Phase I trial, which showed evidence of cholesterol mobilization and excretion (11/28) |
Pharmacyclics Inc. (PCYC) | Antrin | Motexafin lutetium injection | Coronary artery disease | Phase I results presented at the 73rd Scientific Sessions of the American Heart Association show the treatment is well tolerated (11/14) |
Scios Inc. (SCIO) | Natrecor | Recombinant form of B-type natriuretic peptide | Heart failure | Phase III data presented at the 73rd Scientific Sessions of the American Heart Association showed the drug met all end-points; Natrecor improved both the hemodynamic measures associated with acute decompensated congestive heart failure and alleviated dyspnea, or difficulty breathing (11/15) |
Texas Biotechnology Corp. (AMEX:TXB) | Sitaxsentan | Oral endothelin A receptor antagonist | Essential hypertension and pulmonary hypertension | Results from two clinical studies showed patients experienced statistically significant improvements in exercise capacity and hemodynamic improvement, as well as statistically significant reductions in blood pressure; data were presented at the 73rd Scientific Sessions of the American Heart Association (11/10) |
CENTRAL NERVOUS SYSTEM |
||||
Acorda Therapeutics Inc.* | Fampridine SR | Pharmaceutical-grade oral sustained-release formulation of 4-aminopyridine designed to block specialized potassium channels on axons; SR is a nerve conduction-enhancing compound | Multiple sclerosis | Company began a Phase II study that will enroll 30 patients (11/28) |
CV Therapeutics Inc. (CVTX) | Ranolazine | Anti-anginal drug; pFOX (partial Fatty Acid Oxidation) inhibitor | Chronic angina pain | Clinical results presented at the 73rd Scientific Sessions of the American Heart Association suggest ranolazine produces statistically significant increases in exercise duration and time to angina pain, compared to placebo in both younger and older patients (11/14) |
Pozen Inc. (POZN) | MT100 | Oral migraine pain therapeutic | Migraine pain | Company completed two Phase III trials; data will be available in early 2001 (11/28) |
Pozen Inc. (POZN) | MT400 | Combination triptan/nonsteroidal anti-inflammatory | Migraine pain | Company began a Phase II trial with 800 patients (11/28) |
The Immune Response Corp. (IMNR) | BV5S2, BV6S5, BV13S1 | T-cell receptor peptide vaccines combined in Incomplete Freund's Adjuvant, a general immune stimulant | Multiple sclerosis | Company initiated a Phase I/II trial in MS involving 60 patients over 24 weeks (11/14) |
DIABETES |
||||
Alkermes Inc. (ALKS) | Inhaled insulin | Administered from small, simple inhalers | Diabetes | Company completed and analyzed prelininary results from the first clinical trial and initiated a second study (11/27) |
Amylin Pharmaceuticals Inc. (AMLN) | AC2993 | Synthetic exendin-4; a 39-amino acid peptide | Type II diabetes | Company initiated a Phase II study of AC2993 in more than 100 subjects (11/2) |
Insmed Inc. (INSM) | INS-1 | Oral insulin sensitizer | Type II diabetes | Preliminary intent-to-treat analysis showed the drug in combination with sulfonylureas showed no statistical significance from placebo (11/27) |
Insmed Inc. (INSM) | SomatoKine | Composition of insulin-like growth factor-1 and its primary binding protein, BP3 | Type II diabetes | Initial data from a Phase II study showed the drug reduced insulin consumption and average daily blood glucose (11/27) |
Kos Pharmaceuticals Inc. (KOSP) | Niaspan | Formulation of niacin with a statin | Adult-onset diabetes diabetes | Summary findings from a 16-week study of Niaspan in treating lipid abnormalities indicate the drug significantly improves the critical lipoprotein abnormalities in patients without affecting their blood sugar levels (11/14) |
INFECTION |
||||
Aquila Biopharmaceuticals Inc. (AQLA) | QS-21 | Stimulon adjuvant | Flu | Aquila initiated clinical trials of QS-21 as a flu vaccine (11/13) |
MedImmune Inc. (MEDI) | Snyagis | Palivizumab; humanized monoclonal antibody< /TD> |
Respiratory syncytial virus | Results from two studies show the antibody significantly reduces the rate of hospitalization among high-risk infants (11/20) |
Micrologix Biotech Inc. (Canada; TSE:MBI) | MBI 853NL | Anti-infective; intranasally delivered | Staphylococcus aureus infection | Company initiated a Phase Ib trial (11/29) |
Progenics Pharmaceuticals Inc. (PGNX) | PRO 542 | Fusion protein that incorporates HIV binding region of human cell surface receptor (CD4) into a human antibody molecule; binds to GP120 | HIV | Patient treatment has begun in a Phase II study; Phase I/II results were published in the December issue of The Journal of Infectious Diseases (11/28) < /TD> |
Vertex Pharmaceuticals Inc. (VRTX) and Glaxo Wellcome (unit of Glaxo Wellcome plc; UK; NYSE:GLX) | VX-175 (GW433908) | Prodrug of the approved protease inhibitor Agenerase (amprenavir) | HIV | VX-175 entered two separate, 48-week, Phase III pivotal trials (11/27) |
MISCELLANEOUS |
||||
Alkermes Inc. (ALKS) | Medisorb Naltrexone | Injectable sustained-release formulation | Alcoholism and opiate abuse | Trial results indicated the formulation maintained therapeutic levels in the bloodstream for a month following injection (11/21) |
Angiotech Pharmaceuticals Inc. (ANPI) | Micellar paclitaxel | Intravenous therapy of FDA-approved paclitaxel | Severe psoriasis | Angiotech initiated a pilot Phase II study of six patients (11/20) |
Aquasearch Inc. (OTC BB:AQSE) | AstaFactor | Oral astaxanthin-rich algae extract | Exercise-induced asthma | Company will begin a 60-patient clinical trial measuring the compound's ability to decrease airway obstruction (11/17) |
BioChem Pharma Inc. (BCHE) | Zeffix (FDA-approved as Epivir-HBV) | Lamivudine; nucleoside | Cirrhosis analogue (oral) | A study presented at the American Association for the Study of Liver Diseases Congress showed a regression in cirrhosis in 64% of patients with pre-existing cirrhosis following two or more years of treatment with Zeffix (11/1) |
Biomarin Pharmaceutical Inc. (BMRN) and Genzyme General Corp. (GENZ) | Aldurazyme | Recombinant alpha-L-iduronidase | Muccopoly-saccharidosis-1 | Companies entered a pivotal Phase III study with Aldurazyme (11/22) |
Biomatrix Inc. (NYSE:BXM) | Synvisc (FDA-approved) | Hylan G-F20 | Hip osteoarthritis | Study presented at the 64th Annual Meeting of the American College of Rheumatology showed patients exhibited significant and sustained symptomatic relief (11/1) |
Chiron Corp. (CHIR) | TOBI | Tobramycin solution for inhalation | Cystic fibrosis | Data supports the early use of TOBI for cystic fibrosis patients with early lung infections (11/10) |
Corixa Corp. (CRXA) | AnergiX.RA complex | Consists of solubilized HLA DRB1*0401 together with a specific peptide from the human cartilage glyco-protein HCgp39 | Rheumatoid arthritis | Phase I/II results presented at the American College of Rheumatology meeting showed the complex was well tolerated and had biological activity (11/2) |
Epigenesis Pharmaceuticals Inc.* | EPI-2010 | Targets the adenosine A1 receptor | Asthma | Company began a Phase I study (11/2) |
Genmab AS (CSE:GEN; Neuer:GE9) | HuMax-CD4 | Fully human antibody | Rheumatoid arthritis | Company announced positive Phase I/II results showing the drug was well tolerated; results were presented at the American College of Rheumatology Meeting (11/1) |
Immunex Corp. (IMNX) and Wyeth-Ayerst Laboratories (unit of American Home Products Corp.; NYSE:AHP) | Enbrel | Etancercept (FDA-approved) | Uveitis | Results presented at the 64th Annual Meeting of the American College of Rheumatology showed a decrease in inflammation of the uveal tract in 63% of eyes; the trial involved 10 children with chronically active uveitis (11/1) |
Immunex Corp. (IMNX) | Enbrel (FDA-approved) | Etancercept | Rheumatoid arthritis | Clinical data published in The New England Journal of Medicine show that Enbrel can delay progression of structural joint damage in patients with moderately to severely active rheumatoid arthritis (11/30) |
Inspire Pharmaceuticals Inc. (ISPH) | INS365 | P2Y(2) receptor agonist | Dry eye disease | Inspire announced positive results from a Phase II study at the Association for Research in Vision and Ophthalmology meeting; it will soon start a Phase III trial (11/6) |
Micrologix Biotech Inc. (Canada; TSE:MBI) | MBI 594AN | Bactolysin compound (cationic peptide) | Acne | Company initiated a Phase II trial in 75 patients (11/6) |
Neurogen Corp. (NRGN) and Pfizer Inc. (NYSE:PFE) | NGD 91-3 | Modulates specific GABA receptor subtypes | Anxiety disorder | Companies initiated a Phase I study (11/29) |
NexMed Inc. (NEXM) | Alprox TD | Topical treatment | Male erectile dysfunction | NexMed announced Phase II results showing three different dose levels of Alprox-TD were effective over placebo in sexual function endpoint analyses (11/2) |
NicOx SA (France; Nouveau Marche:NICOX) | HCT 1026 | Novel nitric oxide-releasing derivative of the non-steroidal anti-inflammatory compound, flurbiprofen | Skin inflammation | NicOx said HCT 1026 showed potent anti-inflammatory activity and the local and general safety of the ointment was excellent (11/28) |
Regeneron Pharmaceuticals Inc. (REGN) | Axokine | Genetically re-engineered version of a naturally occurring human protein known as ciliary neurotrophic factor | Obesity | Company said Phase II results showed patients had statistically significant weight loss with Axokine as compared to placebo (11/28) |
StressGen Biotechnologies Corp. (Canada; TSE:SSB) | HspE7 | Recombinant fusion protein composed of heat shock protein 65 from Mycobacterium bovis BCG and the protein E7 from HPV type 16 | Anal dysplasia | StressGen initiated patient treatment in a Phase III trial; trial will be double-blind, placebo-controlled, involving 128 patients (11/6) |
Targeted Genetics Corp. (TGEN) | tgAAV-CF | Aerosolized; gene therapy; use of adeno-associated viral vector to deliver normal CFTR (cystic fibrosis transmembrane regulator) gene into nasal passage | Cystic fibrosis | The first patient in a Phase II trial received the drug at Stanford University Medical Center, triggering a $2M milestone payment from Celltech Group plc, of the UK (11/17) |
Vasogen Inc. (Canada; TSE:VAS; AMEX:MEW) | VasoCare | Targets immune processes that lead to inflammatory damage to the lining of blood vessels | Peripheral artery disease | Data showed the drug achieved its primary endpoint; patients treated with VasoCare showed a greater than 50% increase in walking distances compared to placebo (11/29) |